SAD and MAD Study of AKB-9090 in Healthy Adult Participants
Sponsor: Akebia Therapeutics • ClinicalTrials.gov ID: NCT07429006
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with four dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with one dose cohort. Approximately 32 participants in SAD and 12 in MAD are planned to be enrolled.
Interventions
-
AKB-9090
(Drug)
AKB-9090 will be administered intravenously
-
Placebo
(Other)
Matching Placebo administered intravenously
Eligibility criteria
Conditions
Locations
- Investigator Site #1 — Auckland, New Zealand
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record